Back to Search
Start Over
Opna Bio Announces Interim Data from Phase 1 Combination Study of OPN-2853 with Ruxolitinib in Patients with Advanced Myelofibrosis
- Source :
- Business Wire. December 9, 2024
- Publication Year :
- 2024
-
Abstract
- Preclinical Data with OPN-6602 in Multiple Myeloma Show 100% Tumor Regression in Combination Treatment Studies SAN DIEGO -- Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- Business Wire
- Publication Type :
- News
- Accession number :
- edsgcl.819353612